(VIANEWS) – The NYSE opens in less than one hour and Abbott Laboratories‘s pre-market value is already 4.29% down.
Abbott Laboratories’s last close was $118.85, 2.29% below its 52-week high of $121.64.
The last session, NYSE ended with Abbott Laboratories (ABT) dropping 1.09% to $118.85. NYSE slid 0.73% to $17,886.27, following the last session’s downward trend on what was a somewhat bearish trend exchanging session.
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Earnings Per Share
As for profitability, Abbott Laboratories has a trailing twelve months EPS of $3.26.
PE Ratio
Abbott Laboratories has a trailing twelve months price to earnings ratio of 36.46. Meaning, the purchaser of the share is investing $36.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.11%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 2.1% and 3.7%, respectively.
Moving Average
Abbott Laboratories’s value is higher than its 50-day moving average of $114.40 and way above its 200-day moving average of $105.62.
Volume
Today’s last reported volume for Abbott Laboratories is 4937299 which is 34.98% below its average volume of 4965820.
Sales Growth
Abbott Laboratories’s sales growth is 11% for the ongoing quarter and 8.1% for the next.
More news about Abbott Laboratories (ABT).
